Recommendations for the Treatment of Children With Burkitt's Lymphoma

Recruiting now

Conditions studied: Burkitt Lymphoma

In brief

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Key facts

Study ID

NCT04425421

Run by

French Africa Pediatric Oncology Group

People needed

1000

Starts

2020-11-01

Expected to finish

2030-12-31

Last updated by the study team

2026-03-02

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.

You may not qualify if…

• Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.

Where it is running

• Hopital Yalgado Ouedraogo — Ouagadougou, Burkina Faso (enrolling)
• CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (enrolling)
• Cliniques Universitaires de Kinshasa — Kinshasa, Kinshasa City, Democratic Republic of the Congo (enrolling)
• Cliniques Universitaires de Lubumbashi (CUL) — Lubumbashi, Democratic Republic of the Congo (enrolling)
• HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona — Antananarivo, Madagascar (enrolling)
• CHU Gabriel Touré (HGT) — Bamako, Mali (enrolling)
• Hôpital Aristide Le Dantec — Dakar, Senegal (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.